Newsroom

Download PDF Manufacturing of Ficlatuzumab Clinical Supply to Commence in 2Q 2022; Initiation of Registrational Study in HPV Negative R/M HNSCC Expected in 1H 2023 BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with

Download PDF BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022. “I am proud of the entire AVEO team this year, as we accomplished several key milestones in the face of what remains a challenging environment with the ongoing COVID-19 pandemic,” said Michael

Download PDF BOSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th. A webcast of the fireside chat with AVEO’s management team

Download PDF – Former chief operating officer of Enzyvant Therapeutics brings over 20 years of biotech leadership experience – BOSTON–(BUSINESS WIRE)–Dec. 1, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the

Download PDF BOSTON–(BUSINESS WIRE)–Nov. 10, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, todayannounced that members of its senior management team will participate in two upcoming virtual investor conferences: Stifel 2021 Healthcare ConferenceDate: Monday, November 15Time: 1:20 p.m. Eastern Time 4th Annual Evercore ISI Healthconx ConferenceDate: Tuesday, November 30Time: 12:35 p.m. Eastern Time A webcast of the fireside chats, or

Download PDF – Total Q3 2021 Revenue of $15.2 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $14.3 Million –– Enrollment Open for Pivotal Phase 3 TiNivo-2 Clinical Trial of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) –– Ficlatuzumab and ERBITUX® (cetuximab) Granted Fast Track Designation by the U.S. FDA for R/R HNSCC; Potential Registrational Clinical Trial Expected to Commence in 1H 2023 –– Company to

Download PDF BOSTON–(BUSINESS WIRE)–Nov. 1, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, November 8, 2021, to discuss the financial results and provide a business

Download PDF BOSTON–(BUSINESS WIRE)–Sep. 20, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma (R/R HNSCC). Ficlatuzumab is AVEO’s investigational potent humanized immunoglobulin G1